Adimab's Collaborator GSK Celebrates New Approvals for Depemokimab in Europe and China Adimab congratulates GSK for gaining new marketing approvals for depemokimab in Europe and China. This marks a significant advancement in biopharmaceuticals.

Adimab's Collaborator GSK Celebrates New Approvals for Depemokimab in Europe and China #United_States #GSK #Lebanon #Adimab #Depemokimab

Adimab Achieves Significant Growth in Clinical Programs for 2025 Adimab has reported impressive growth in its clinical programs, launching 11 new initiatives in 2025 and achieving notable market approvals.

Adimab Achieves Significant Growth in Clinical Programs for 2025 #USA #Clinical_Trials #Lebanon,_NH #Antibody_Discovery #Adimab

Adimab Sees Record Growth in Partnerships and New Programs for 2025 In 2025, Adimab achieved remarkable success with 23 new partnerships and 75 additional therapeutic programs, leading the industry in antibody discovery.

Adimab Sees Record Growth in Partnerships and New Programs for 2025 #None #partnerships #Therapeutic_Antibodies #Adimab